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Summary
In the world exists more international [1, 2], supranational (regional) [3, 4], and national programs [5-15] aimed to 
survey the usage of antibiotics, involving dozens of countries which have thousands of hospitals and other public health 
institutions.  The article aims at collating and evaluating data on antibiotics usage in the National Practical-Scientifi cal 
Centre of Emergency Medicine over a certain time. Present research covers antibiotics utilization data, as a rate based on 
defi ned daily doses, enables reporting and comparison of total-hospital usage for the period from January 2009 to January 
2012. The average annual rate for total-hospital antibiotics utilization of defi ned daily doses per 1000 occupied occupied-
bed days since 2009 had decreased from 662.4 to 542.4 in 2012. This report provides data which could be used to target 
particular areas of antibiotics usage.  At the hospital level the usage trends is a parameter for identifying overall changes 
in prescribing practices. 
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Rezumat. Evaluarea consumului de antibiotice în doze defi nite pentru o zi în spitalele din Republica Moldova
În lume există mai multe programe intrenaţionale [1, 2], regionale [3, 4] şi naţioanle [5-15] scopul cărora este 
evaluarea consumului de antibiotice şi în care participă zeci de ţări cu un număr de mii de spitale şi alte instituţii medicale. 
În prezentul studiu a fost evaluat consumul de antibiotice în doze defi nite pentru o zi pe întreaga instituţie în perioada 
din ianuarie 2009 până în ianuarie 2012. Media anuală pentru totalul consumului de antibiotice în doze defi nite pentru 
o zi pentru 1000 de paturi-zile ocupate din anul 2009 s-a micşorat de la 662,4 până la 542,4 în anul 2012. În urma 
prezentei evaluări sunt obţinute date care pot fi  utilizate pentru optimizarea utlizării antibioticelor inclusiv şi pеntru cazuri 
particulare. 
Cuvinte cheie: antibiotic, consum, spital, program, doze defi nite pentru o zi, zile-pat ocupate, utilizare raţională     
Аннотация. Изучение показателей среднесуточного расхода определенных доз антибиотиков в 
лечебных учреждениях Республики Молдова
В настоящее время в мире действует ряд международных [1, 2] зональных [3, 4] и многонациональных 
[5-15] программ в которых принимают участие тысячи госпиталей и других лечебных учреждений десятков 
стран. Основной целью проводимых исследований является мониторинг расхода антибактериальных препаратов. 
В данной работе изложены результаты изучения показателей среднесуточного расхода определенных доз 
антибиотиков в лечебном учреждении в период с января 2009 по январь 2012 года. Продемонстрировано снижение 
расхода определенных среднесуточных доз антибиотиков в расчете на 1000 занятых больничных коек с 662.4 
в 2009 г. до 542.4 в 2012 году. Выводы сделанные на базе полученного материала могут быть использованы 
для выработки рекомендаций направленных на оптимизацию применения  антибактериальных препаратов как в 
данном конкретном лечебном учреждении, так и в целом по стране.
Ключевые слова: антибиотик, расход, госпиталь, программа,  определенная среднесуточная доза, занятые 
койко-дни, рациональное использование                                                                       
Introduction
National Scientifi cal-Practicalal Centre of 
Emergency Medicine of the Republic of Moldova 
(NSPCEM), was founded in 1959. Clinical Services 
of include: Orthopedic-Traumatology Clinic for 150 
beds, Surgery Clinic for 150 beds, Neurosurgery 
Clinic for 80 beds, Neurology Clinic for 70 beds, 
Maxillo-facial clinic for 30 beds, Urology Clinic for 
40 beds, Gynecology Clinic for 30 beds, Microsurgery 
Clinic for 30 beds, Municipal Center with 8 seats 
hemodialysis and 9 beds, Clinical intensive care unit 
for 30 beds, in total the above services of the NPSCEM 
include 619 beds, also includes 5 emergency medical 
help substation and 4 out-patient department of 
traumatology and orthopedics [16].
The primary aim of the study was to evaluate 
institutional representative data on antibiotics 
utilization for a period of four years (2009-2012), 
according to World Health Organization (WHO) 
requirements to determine value of Defi ned Daily 
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Doses (DDD) per 1000 occupied Occupied-Bed 
Days (OBD) and comparing these data with the 
results of the use of antibiotics in hospitals from other 
countries.  Based on obtained data it aimed to make 
conclusions on the use of antibiotics in the institution 
and to propose recommendations for ensuring the 
optimization with antibiotics.
To determine DDD and compare the consumption 
of antibiotics for the period of 2009-2012, the statistics 
data concerning the number of treated patients (for 
only patients with health insurance and other free 
treated by the state categories of citizens), the number 
of bed/days and total annual quantities of antibiotics 
were used.  The number of patients treated in the 
institution was 20946 in 2009, 21341 in 2010, 19913 
in 2011 and 20664 in 2012 [17].
Because the Republic of Moldova is a developing 
country, today neither group of medical institutions 
or medical institution in general are having their 
own program or are participating in international or 
regional programs that deal with of antimicrobial use 
surveillance.
Antimicrobial data are aggregated over the time 
period of interest at hospital level and converted to 
standardized usage rates based on the WHO defi nition 
of DDD with 1000 OBD as the denominator.
Units of measurement
1.  Defi ned daily doze (DDD)
The DDD for any drug is defi ned as the average 
dose per day to treat the main indication for an average 
adult patient according to the main indication.  The 
WHO has determined DDDs standards for most 
drugs and these values have been used in calculating 
usage rates.  The use of this internationally accepted 
standard enables to compare the usage of antibiotics 
with differing doses and with data from other 
surveillance programs or studies.
The number of defi ned daily doses used is 
calculated as follows:
                             Total grams used
The number of DDD = ---------------------------------
                                 WHO assigned DDD value
2. Occpied bed days (OBD)
Occupied Bed Days are defi ned as the sum of 
the lengths of stay for each acutely adult inpatient 
detached during the reporting period that remained in 
hospital overnight [11, 13].  Day patients, outpatients, 
hospital-in-the-home and rehabilitation units in OBD 
are excluded.
In this research were not included the data about 
antibiotics ointments and eye drops consumption.
3. List of antibiotics with DDD used in NSPCEM 
(annex 1).
Aggregation of contributed data into therapeutic 
group allows: 
Assessment of relative use of particular - 
classes;
Benchmarking with usage data from similar - 
studies;
Comparison with the consumption of different - 
periods of time.
Organization of study
For calculated antimicrobial Defi ned Daily Doses 
(DDDs) and DDDs per 1000 patient days [18] and 
other comparison analysis have been followed several 
steps:
Step 1: Performed encoding of each antibiotics 
remedy according to the WHO ATC classifi cation in 
the drug record institutional system.
Step 2: The report on drugs consumption for the 
period of four years (2009-2012) has been obtained and 
then ensconced in accordance with ATC classifi cation 
groups and subgroups of antibiotics. 
Step 3: The conversion of all antibiotics usage to 
grams (or million units (MU)) where applicable.
Step 4: Obtained WHO assigned DDD value 
for utilizing antibacterials in NSPCEM from WHO 
Collaborating Centre for Drug Statistics Methodology 
Norwegian Institute of Public Health.
Step 5: To obtain yearly DDD for every antibiotics 
in the year 2009; 2010; 2011 and 2012 was divided the 
amount of grams of all antibiotics to WHO assigned 
DDD value.
Step 6: The DDD per one OBD has been obtained; 
therefore, the totals for each antibiotics in the years 
2009; 2010; 2011 and 2012 and total annual DDD, 
was divided to a numbers of total occupied bed/days 
for the respective period of time. 
Step 7: It was obtained the DDD/1000 OBD; 
therefore, the obtained DDD per one occupied day 
for every antibiotics and the total for the respective 
period of time, was multiplied by 1000.
Step 8: It was obtained the total of DDD/1000 
occupied bed/days for every groups and subgroups 
of antibiotics.  For that was accounted every 
antibiotics DDD/1000 OBD for respective groups 
and subgroups.
Step 9: It was determined separate data of 
parenteral and oral administration for the evaluation 
period of antibiotics.
Step 10: Based on the collected data from others 
scientifi c research was compare percentage of a total 
consumption and subgroups of antibiotics.
The evaluations results
Total-institutional for period of 2009-2012 yeas 
of antibiotics usage rate.
In fi gure 1 is demonstrated the total antibiotics 
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use rates of DDD/1000 OBD by WHO antibiotic 
groups (Parenteral and Oral Usage) in NSPCEM. 
The average aggregate annual rate for total-hospital 
antibiotics utilization period decreased from 662.4 
DDD/1000 OBD in 2009 to 542.4 DDD/1000 OBD 
in 2012, or by 18, 12% (Fig. 1).  
Annual usage rate data, aggregated by year and 
therapeutic group, for four years from January 2009 
to January 2012, demonstrated a decline in usage rates 
for tetracyclines by 13.41%, beta-lactam antibiotics, 
penicillin by 10.41%, other beta-lactam antibiotics 
16.69%, sulfonamides and trimethoprim from 5.7 
to 0 DDD/1000 OBD, macrolides and lincosamides 
by 20.01%, quinolone antibiotics by 42.53%, other 
antibiotics by 58.97%, equally a unstable use of 
amphenicols and an encreased consumption for 
aminoglycoside antibiotics by 24.19% and and 
antimycotics for systemic by 32.23%.  The usage rate 
for 2012 is showen near every grupe of antibiotics.
In fi gure 2 is presented trends of usage rates 
DDD/1000 OBD by WHO antibiotic groups (Parenteral 
Usage) in NSPCEM.  The average consumption 
annual rate in the evaluation period for total-hospital 
antibiotics for parenteral usage decreased from 568.9 
DDD/1000 OBD in 2009 to 460.10 DDD/1000 OBD 
in 2012, or by 19.13% (Fig. 2).  
Fig. 1.  Total antibiotics usage rates DDD/1000 OBD in 2009-2012 
(Parenteral and Oral Usage)
Fig. 2.  Total antibiotics usage rates DDD/1000 OBD in 2009-2012 (Parenteral Usage)
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A signifi cant decrease usage was registered for 
quinolone antibiotics by 65.71% and other antibiotics 
by 52.85%, a decline in usage rates for beta-lactam 
antibiotics by 14.30%, other beta-lactam antibiotics 
with 20.60%, macrolides, lincosamides and 
streptogramins by 21.05%, and an encreased usage 
for aminoglycoside for systemic by 19.48%.  An 
approximate constant yearly average consumption 
was registered for amphenicols.
In fi gure 3 are presented trends in large groups of 
antibiotics for oral use in NPSCEM in the evaluation 
period.  The average consumption annual rate of 
antibiotics for oral usage decreased from 93.28 
DDD/1000 OBD in 2009 to 82.25 DDD/1000 OBD 
in 2012, or by 11.83 %.  The usage rate for 2012 is 
showen near every grupe of antibiotics (Fig. 3).  
A signifi cant increase of usage was registered 
for beta- antibiotics by 44, 64%, other beta-lactam 
antibiotics by 82.26% and antimycotics for systemic 
by 19.01%.  An unstabile usage was registered 
for tetracyclines, amphenicols and  macrolides, 
lincosamides, sulfonamides and trimethoprim.  The 
usage rate for 2012 is showen niar every grupe of 
antibiotics.
The annual trends consumption of antibiotics for 
parenteral and oral use is presented in table 1.
We can state that the usage trends of antibiotics 
for parenteral and oral use during the evaluated 
period, had been recorded approximately a constant 
percentage in comparison with the total consumption 
of all antibiotics, and, ranged for parenteral use with 
1-1.1% (85.9%-84.8%) a slight decrease, and for oral 
use with 1-1.1% (14.1%-15.2%) a slight increment.
The percentage usage trends of DDD/1000 OBD 
per day of antibiotics group ATC J01 between the 
NPSCEM of Republic of Moldova and seven courtiers 
from Europe Union, such as: Bulgaria, Ireland, 
Estonia, Lithuania, Latvia, Sweden and Finland are 
presented in table 2.
Utilizing the DDD/1000 OBD per day data [19], 
we have calculated the percentage usage trends for 
the large antibiotics groups ATC J01 between the 
NSPCEM and seven courtiers from Europe Union. 
The results demonstrate that the average proportion 
of consumption in seven courtiers from Europe 
Union and NSPCEM are for tetracyclines 3.4:1, beta-
lactam antibiotics 1.9:1, other beta- antibiotics 0.8:1, 
macrolides, lincosamides and streptogramins 1.1:1, 
quinolone antibiotics 1:1, other antibiotics 0.7:1. 
In table 3 is presented total-hospital usage rates 
of DDD/1000 OBD of antimicrobials between the 
NSPCEM and eleven international researches with the 
data from more than 2000 hospitals from European 
countries.
Fig. 3.  Total antibiotics usage rates DDD/1000 OBD in 2009-2012 (Oral Usage)
Table 1 
Trends of antibiotics for parenteral and oral usage in NSPCEM in 2009-2012
TOTAL parenteral 568.9 85,9% 471.6 84,5% 521.5 78,7% 460.1 84,8%
TOTAL oral 93.28 14,1% 86.6 15,5% 100.58 21,3% 82.25 15,2%
TOTAL 662.2 558.2 622.1 542.4
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The results shows, that in NPSCEM the 
consumption of antibiotics in comparison with ten 
international researches [20, 21, 22, 23, 24, 25, 26, 
27, 28, 4] is at medium, with 9,06 % more. Where 
in fi ve international researches the comparison is at 
medium with 25% more, in four around the same and 
in one case less than 29%.
Antibiotic class use rates in the period of 
January 2009 to January 2012
In fi gure 4 is presented the use rates of tetracycline 
(Doxycyclinum), amphenicols (Chloramphenicolum), 
penicillins with extended spectrum (Ampicillinum, 
Amoxicillinum) and combinations of penicillins, incl. 
beta-lactamase inhibitors (Amoxicillinum+Acidum 
clavulanicum, Ticarcillinum + Acidum clavulanicum) 
(Fig. 4).  
For the evaluated period is noted a general 
decrease by 10,62% of consumption of the mentioned 
grupes of antibiotics.  Where decreased on one hand 
of tetracyclines by 13,42%, amphenicols by 0%, 
penicillins with extended spectrum by 13,88 times, on 
the other hand an increased of penicillins combination, 
incl. beta-lactamase inhibitors by 9,1 times.
The use rates of cephalosporins fi rst generation 
(Cefalexinum, Cefazolinum), second generation 
(Ce fu ro ximum, Cefaclorum), third generation (Ce-
fotaximum, Ceftazidimum, Ceftriaxonum, Cefi xi mum, 
Cefoperazonum, Cefoperazonum and Sulbactamum) 
and carbapemens (Meropenemum, Imipenemum and 
Cilastatinum) are presented in fi gure 5.
From this fi gure we can differentiate two periods 
of concumption.  First period 2009-2011 where fi rst 
generation of cephalosporins decreased usage by 
3,25 times, while the second and third generations of 
cephalosporins had increased the usage respectively 
by 2,83 and 2,70 times, and second period 2011-2012 
where fi rst generation of cephalosporins increased 
usage by 1,73 times, while the second and hird 
generations of cephalosporins had decreased the usage 
respectively by 4,96 times and 34,36%.  At all in the 
evaluation period fi rst generation of cephalosporins 
decreased the usage by 46,83%, second generation of 
Table 2 











Tetracyclines 1.33 1.42 1.12 4.44 2.5 3.0 12.01 7.5
Beta-lactam
Penicilins 14.12 20.0 9.44 32.77 24.16 30.33 50.66 18.57
Other Beta-lactam
antibiotics 41.59 51.44 49.44 26.11 22.5 37.66 13.33 32.5
Macrolides
Lincosamides and streptogramins 6.54 7.85 14.44 10.55 2.5 4.33 4.0 5.35
Quinolone
antibiotics 9.64 7.85 7.77 10.55 6.25 11.66 10.66 12.14
Other antibiotics 26.78 14.28 14.44 14.15 40.41 10.66 7.33 20.71
J01 between the NPSCEM of Republic of Moldova and seven European courtiers
Table 3 
Comparison of total-hospital usage rates of DDD/1000 OBD of antibiotics between 
the NPSCEM and ten international researches
Hospitals DDD/1000
Percentage consumption in the 
NSPCEM in comparison with eleven 
researchers
NSPCEM of Republic of Moldova 542.4 542.4 = 100%
34 public/43 private hospitals in France [20] 395/422 72.82%-77.80%
Antibiotic use in 530 French hospitals [21] 62.3–557.7 11.45%-102.82%
University Hospital of Geneva [22] 400 73,74%
Besancon University Hospital French [23] 535.4 98,71%
74 south-western French hospitals [24] 400-450 73.75%-82.97%
University Medical Center Rotterdam
The Netherlands [25] 547 100.85%
1115 hospitals in France [26] 370-393 68.22% - 72,45%
University Hospital Huddinge, Sweden [27] 430 79.28%
139 hospitals from 30 European countries [28] 496 91.45%
All hospitals in Netherlands [4] 702 129.43%
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cephalosporins by 43,01%, while third generations 
of cephalosporins increased the consumption with 
43,91%.  The total consumption of other beta-lactam 
antibiotics from the evaluation period had deceased 
with 16.69%.
The usage rates of macrolides (Erytromycinum, 
Midecamycinum, Clarithromycinum, Azithro-
my ci num), lincosamides (Lincomycinum), other 
aminoglycosides (Gentamycinum, Kanamycinum, 
Amikacinum) and fl uoroquinolones (Ofl oxacinum, 
Ciprofl oxacinum, Norfl oxacinum, Mofl oxacin, 
Gatifl oxacinum, Acidum pipemidicum) from 2009 
till 2012 is presented in fi gure 6.
In this fi gure we can see an aproximately 
proportional consumption of all those subgroups of 
antibiotics in 2009 and 2011 as well in 2010 and 2012 
without other aminoglycosides.  All the evaluation 
period is characterised with an instabil consumption, 
an increased and decreased around and more than 
50%, of usage of each grup of those antibiotics.
In fi gure 7 is presented the usage rates of 
antibiotics (Vancomycinum), imidazole derivatives 
(Metronidazolum), nitrofuran derivatives (Furazi-
dinum, Nitrofurantoinum) and other antibacterials 
(Dioxydinum, Nitroxolinum).
From 2009 to 2012 the usage rates of other 
antibiotics had decreased by 58,43%, from which: 
imidazole derivatives by 55,93%, nitrofuran 
derivatives by 85,86%.  Other antibiotics and 
glycopeptide antibiotics had encountered a low and 
instabil consumption.
The usage rates of antimycotics for systemic use 
are presented in fi gure 8.
As seen in this fi gure, the total consumption 
of this group in the evaluation period increased by 
32,23%, from which usage of imidazole derivatives 
Fig. 4.  The use rates of tetracyclines, amphenicols, beta-lactam antibiotics and penicillins DDD/1000 
per DAY in 2009-2012
Fig. 5. Usage rates of other beta-lactam antibiotics DDD/1000 per DAY in 2009-2012
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Fig. 8. Usage rates of antimycotics for systemic use DDD/1000 per DAY in 2009-2012
Fig. 6.  Usage rates of macrolides, lincosamides and aminoglycosides and quinolone antibiotics 
DDD/1000 per DAY in 2009-2012
Fig. 7.  Usage rates of glycopeptide antibiotics, imidazole derivatives, nitrofuran derivatives and other 
antibiotics DDD/1000 per DAY in 2009-2012
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(Ketoconazolum) encoutered a high usage in 
2010 by 5,91 times more and triazole derivatives 
(Fluconazolum) in 2011 with 41,82% more 
comparative with 2009.
Conclusions
The average annual rate for total-hospital 1. 
antibiotics utilization of Defi ned Daily Doses per 
1000 occupied Occupied-Bed Days (DDD/1000 
OBD) since 2009 had decreased from 662,4 to 542,4 
or by 18,12%, where antibiotics for parenteral and 
oral usage represents respectively 568,9 to 460,1 and 
93.28 to 82,25 or a medium of 85% and 15%.
The percentage usage trends of DDD/1000 2. 
OBD per day of ATC J01 antibiotics groups, from the 
total in the NSPCEM, in comparison with the same 
medium percentage of seven courtiers from Europe 
Union, demonstrated that the greater differences 
of this proportion are in tetracyclines (1:3.4) and 
beta-lactam antibiotics (1:1.9). The consumption of 
DDD/1000 OBD per day antibiotics in comparison 
with ten international researches is at medium with 
9,06% more.  From which in fi ve more than 25%, in 
four around the same and in one case less than 29%.
The utilization spectrum of antibiotics for 3. 
systemic use in the evaluation period includes 10 
groups with 18 subgroups of antibiotics.  In 2012 three 
antibiotic classes with the rate of DDD/1000 OBD per 
day of total consumption more than 10% reprezents 
(beta-lactam with 14,12%, other beta-lactam with 
41,59% and aminoglycozide antibiotics with 19,03%) 
which accounts 74,74%, other three antibiotics classes 
with consumption between 3% and 10% of the total 
reprezents (macrolides and lincosamides with 6,54%, 
quinolone antibiotics with 9,64% and other antibiotics 
with 4,7%) which accounts 20.88% and the last three 
antibiotic classes with consumption less than 3% 
reprezents (tetracyclines with 1,33%, aminophenols 
with 0,09% and antimycotics for sistemic use) which 
accounts 4,38%.
From the evaluation period was determened a 4. 
considerable decreased in consumption of DDD/1000 
OBD per day of penicillins with extended spectrum 
from 77,7 to 5,6 or by 13,88 times, fi rst and second 
generation of cephalosporins respectively from 192,2 
to 102,2 and 13,16 to 7,5 or with 46.83% and 43,01%, 
imidazole and nitrofuran derivatives from 50.6 to 
22,3 and 9,9 to 1,4 or with 55,93% and 85,86%, an 
increased in consumption of penicillins combination, 
incl. beta-lactamase inhibitors by 9,1 times and 
third generations of cephalosporins by 43,91%.  An 
insabil consumption has been found of macrolides, 
lincosamides, aminoglycosides and quinolone 
antibiotics.
One of the objectives of the present research, 5. 
results in a clearly demonstration that the health system 
of the Republic of Moldova have not implemented 
any internationally recognized unites and programs 
to measure the drugs utilization studies.  This puts 
the entire health care system in terms of inability 
to compare the consumption of drugs with similar 
institutions of other health systems and, therefore, 
disabling the qualitative determination of planning 
the necessary drugs and their rational use.
Suggestions
First of all the proposal is to introduce in 1. 
the practice of medical institutions of the Republic 
of Moldova the ATC/DDD as an internationally 
recognized tool for the drug utilization research 
in order to improve the quality of drug use, the 
comparison of drugs’ consumption statistics at 
international, regional, national and other levels.
Based on WHO and others research programs, 2. 
it is rational to elaborate and further adopt a state 
program to survey the antibiotics use.
To estimate a structure at the national health 3. 
system level for the practical implementation, that 
will:
- Provide regular and qualitative feedback to 
contributing hospitals, enabling examination of 
antibiotics usage rates and identifi cation usage targets 
for intervention programs;
- Examine trends in antibiotics use at state and 
national levels to inform large scale interventions to 
rationalize hospital antibiotics prescribing;
- Provide our institutional peer group benchmark 
and enable comparison with other international 
institutional data and increased healthcare costs, and 
others goals.
4. To continue research in the National Scientifi c 
and Practical Centre of Emergency Medicine in 
main directions, fi rst all in intensive care unites and 
other departments with high and low consumption of 
antibiotics of systemic use as infectious departments 
of surgery and orthopedic.
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Annex 1 
WHO Defi ned Daily Doses (DDD) for utilizing antibacterials in
National Scientifi c and Practical Centre of Emergency Medicine (NSPCEM)
ATC classifi cation International name of antibacterials ROUTE DDD (g)
J J ANTIINFECTIVES FOR SYSTEMIC USE
J01 J01 ANTIBACTERIALS FOR SYSTEMIC USE
J01A J01A TETRACYCLINES
J01AA02 Doxycyclinum O 0,1
J01B J01B AMPHENICOLS
J01BA J01BA Amphenicols
J01BA01 Chloramphenicolum O 3
J01BA01 Chloramphenicolum P 3
J01C
J01C BETA-LACTAM ANTIBACTERIALS, 
PENICILLINS
J01CA J01CA Penicillins with extended spectrum
J01CA01 Ampicillinum O 2
J01CA01 Ampicillinum P 2
J01CA04 Amoxycillinum O 1
J01CA04 Amoxycillinum P 1
J01CR J01CR Combinations of penicillins, incl. beta-lactamase inhibitors
J01CR02 Amoxicillinum + Acidum clavulanicum O 1
J01CR02 Amoxicillinum + Acidum clavulanicum P 3
J01CR03 Ticarcillinum + Acidum clavulanicum P 15
J01D J01D OTHER BETA-LACTAM ANTIBACTERIALS
J01DB J01DB First-generation cephalosporins
J01DB01 Cefalexinum O 2
J01DB04 Cefazolinum P 3
J01DC J01DC Second-generation cephalosporins
J01DC02 Cefuroximum O 0,5
J01DC02 Cefuroximum P 3
J01DC04 Cefaclorum O 1
J01DD J01DD Third-generation cephalosporins
J01DD01 Cefotaximum P 4
J01DD02 Ceftazidimum P 4
J01DD04 Ceftriaxonum P 2
J01DD08 Cefi xim O 0,4
J01DD12 Cefoperazonum P 4
J01DD62 Cefoperazonum + Sulbactamum P 4
J01DH J01DH Carbapenems
J01DH02 Meropenemum P 2
J01DH51 Imipenemum+Cilastatinum P 2
J01E J01E SULFONAMIDES AND TRIMETHOPRIM
J01EE J01EE Combinations of sulfonamides and trimethoprim, incl. derivatives
J01EE01 Sulfamethoxazolum + Trimethoprimum O 1,9
J01F J01F MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
J01FA J01FA Macrolides
J01FA01 Erytromycin O 1
J01FA03 Midecamycinum O 1
J01FA09 Clarithromycinum O 0,5
J01FA09 Clarithromycinum P 0,5
J01FA10 Azithromycinum O 0,3
J01FA10 Azithromycinum P 0,5
J01FF J01FF Lincosamides
J01FF02 Lincomycinum P 1,8
J01G J01G AMINOGLYCOSIDE ANTIBACTERIALS
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J01GA J01GA Streptomycins
J01GA01 Streptomycinum P 1
J01GB J01GB Other aminoglycosides
J01GB03 Gentamycinum P 0,2
J01GB04 Kanamycinum P 1
J01GB06 Amikacinum P 1
J01M J01M QUINOLONE ANTIBACTERIALS
J01MA J01MA Fluoroquinolones
J01MA01 Ofl oxacinum O 0,4
J01MA01 Ofl oxacinum P 0,4
J01MA02 Ciprofl oxacinum O 1
J01MA02 Ciprofl oxacinum P 0,5
J01MA06 Norfl oxacinum O 0,8
J01MA14 Mofl oxacin P 0,4
J01MA16 Gatifl oxacinum O 0,4
J01MA16 Gatifl oxacinum P 0,4
J01MB04 Acidum pipemidicum O 0,8
J01MB04 Acidum pipemidicum P 0,8
J01R J01R COMBINATIONS OF ANTIBACTERIALS
J01RA Ciprofl oxacinum + Tinidazolum O 2
J01X J01X OTHER ANTIBACTERIALS
J01XA J01XA Glycopeptide antibacterials
J01XA01 Vancomycinum P 2
J01XD J01XD Imidazole derivatives
J01XD01 Metronidazolum P 1,5
J01XE J01XE Nitrofuran derivatives
J01XE,G01AX Furazidinum O 0,2
J01XE01 Nitrofurantoinum O 0,2
J01XX J01XX Other antibacterials
J01XX Dioxydinum P 0,7
J01XX07 Nitroxolinum O 1
J02AB J02AB Imidazole derivatives
J02AB02 Ketoconazolum O 0,2
J02AC J02AC Triazole derivatives
J02AC01 Fluconazolum O 0,2
J02AC01 Fluconazolum P 0,2
P = parenteral, O = oral
WHO Defi ned Daily Doses (DDD) for utilizing antibacterials in
National Scientifi c and Practical Centre of Emergency Medicine (NSPCEM)
ATC classifi cation International name of antibacterials ROUTE DDD (g)
J J ANTIINFECTIVES FOR SYSTEMIC USE
J01 J01 ANTIBACTERIALS FOR SYSTEMIC USE
J01A J01A TETRACYCLINES
J01AA02 Doxycyclinum O 0,1
J01B J01B AMPHENICOLS
J01BA J01BA Amphenicols
J01BA01 Chloramphenicolum O 3
J01BA01 Chloramphenicolum P 3
J01C J01C BETA-LACTAM ANTIBACTERIALS, PENICILLINS
J01CA J01CA Penicillins with extended spectrum
J01CA01 Ampicillinum O 2
J01CA01 Ampicillinum P 2
J01CA04 Amoxycillinum O 1
J01CA04 Amoxycillinum P 1
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J01CR J01CR COMBINATIONS OF PENICILLINS, INCL. BETA-LACTAMASE INHIBITORS
J01CR02 Amoxicillinum + Acidum clavulanicum O 1
J01CR02 Amoxicillinum + Acidum clavulanicum P 3
J01CR03 Ticarcillinum + Acidum clavulanicum P 15
J01D J01D OTHER BETA-LACTAM ANTIBACTERIALS
J01DB J01DB First-generation cephalosporins
J01DB01 Cefalexinum O 2
J01DB04 Cefazolinum P 3
J01DC J01DC Second-generation cephalosporins
J01DC02 Cefuroximum O 0,5
J01DC02 Cefuroximum P 3
J01DC04 Cefaclorum O 1
J01DD J01DD Third-generation cephalosporins
J01DD01 Cefotaximum P 4
J01DD02 Ceftazidimum P 4
J01DD04 Ceftriaxonum P 2
J01DD08 Cefi xim O 0,4
J01DD12 Cefoperazonum P 4
J01DD62 Cefoperazonum + Sulbactamum P 4
J01DH J01DH Carbapenems
J01DH02 Meropenemum P 2
J01DH51 Imipenemum+Cilastatinum P 2
J01E J01E SULFONAMIDES AND TRIMETHOPRIM
J01EE J01EE Combinations of sulfonamides and trimethoprim, incl. derivatives
J01EE01 Sulfamethoxazolum + Trimethoprimum O 1,9
J01F J01F MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
J01FA J01FA Macrolides
J01FA01 Erytromycin O 1
J01FA03 Midecamycinum O 1
J01FA09 Clarithromycinum O 0,5
J01FA09 Clarithromycinum P 0,5
J01FA10 Azithromycinum O 0,3
J01FA10 Azithromycinum P 0,5
J01FF J01FF Lincosamides
J01FF02 Lincomycinum P 1,8
J01G J01G AMINOGLYCOSIDE ANTIBACTERIALS
J01GA J01GA Streptomycins
J01GA01 Streptomycinum P 1
J01GB J01GB Other aminoglycosides
J01GB03 Gentamycinum P 0,2
J01GB04 Kanamycinum P 1
J01GB06 Amikacinum P 1
J01M J01M QUINOLONE ANTIBACTERIALS
J01MA J01MA Fluoroquinolones
J01MA01 Ofl oxacinum O 0,4
J01MA01 Ofl oxacinum P 0,4
J01MA02 Ciprofl oxacinum O 1
J01MA02 Ciprofl oxacinum P 0,5
J01MA06 Norfl oxacinum O 0,8
J01MA14 Mofl oxacin P 0,4
J01MA16 Gatifl oxacinum O 0,4
J01MA16 Gatifl oxacinum P 0,4
J01MB04 Acidum pipemidicum O 0,8
J01MB04 Acidum pipemidicum P 0,8
J01R J01R COMBINATIONS OF ANTIBACTERIALS
J01RA Ciprofl oxacinum + Tinidazolum O 2
Buletinul AŞM200
J01X J01X OTHER ANTIBACTERIALS
J01XA J01XA Glycopeptide antibacterials
J01XA01 Vancomycinum P 2
J01XD J01XD Imidazole derivatives
J01XD01 Metronidazolum P 1,5
J01XE J01XE Nitrofuran derivatives
J01XE,G01AX Furazidinum O 0,2
J01XE01 Nitrofurantoinum O 0,2
J01XX J01XX Other antibacterials
J01XX Dioxydinum P 0,7
J01XX07 Nitroxolinum O 1
J02AB J02AB Imidazole derivatives
J02AB02 Ketoconazolum O 0,2
J02AC J02AC Triazole derivatives
J02AC01 Fluconazolum O 0,2
J02AC01 Fluconazolum P 0,2
P = parenteral, O = oral
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